Cited by 2,323COVID-19 Clinical Research StudiesSARS-CoV-2 and COVID-19 ResearchRespiratory viral infections research

The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.

Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19

Open access

Hammond, Jennifer, Leister-Tebbe, Heidi, Gardner, Annie, Abreu, Paula, Bao, Weihang, Wisemandle, Wayne, Baniecki, MaryLynn, Hendrick, Victoria M., Damle, Bharat, Simón-Campos, Abraham, Pypstra, Rienk, Rusnak, James M.·2022·New England Journal of Medicine

DOI 10.1056/nejmoa2118542PMC PMC8908851

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUNDNirmatrelvir is an orally administered severe acute respiratory syndrome coronavirus 2 main protease (M pro ) inhibitor with potent pan-human-coronavirus activity in vitro. METHODSWe conducted a phase 2-3 double-blind, randomized, controlled trial in which symptomatic, unvaccinated, nonhospitalized adults at high risk for progression to severe coronavirus disease 2019 (Covid-19) were assigned in a 1:1 ratio to receive either 300 mg of nirmatrelvir plus 100 mg of ritonavir (a pharmacokinetic enhancer) or placebo every 12 hours for 5 days.Covid-19-related hospitalization or death from any cause through day 28, viral load, and safety were evaluated. RESULTSA total of 2246 patients underwent randomization; 1120 patients received nirmatrelvir plus ritonavir (nirmatrelvir group) and 1126 received placebo (placebo group).In the planned interim analysis of patients treated within 3 days after symptom onset (modified intention-to treat population, comprising 774 of the 1361 patients in the full analysis population), the incidence of Covid-19-related hospitalization or death by day 28 was lower in the nirmatrelvir group than in the placebo group by 6.32 percentage points (95% confidence interval [CI], -9.04 to -3.59; P<0.001; relative risk reduction, 89.1%); the incidence was 0.77% (3 of 389 patients) in the nirmatrelvir group, with 0 deaths, as compared with 7.01% (27 of 385 patients) in the placebo group, with 7 deaths.Efficacy was maintained in the final analysis involving the 1379 patients in the modified intention-to-treat population, with a difference of -5.81 percentage points (95% CI, -7.78 to -3.84; P<0.001; relative risk reduction, 88.9%).All 13 deaths occurred in the placebo group.The viral load was lower with nirmatrelvir plus ritonavir than with placebo at day 5 of treatment, with an adjusted mean difference of -0.868 log 10 copies per milliliter when treatment was initiated within 3 days after the onset of symptoms.The incidence of adverse events that emerged during the treatment period was similar in the two groups (any adverse event, 22.6% with nirmatrelvir plus ritonavir vs. 23.9% with placebo; serious adverse events, 1.6% vs. 6.6%; and adverse events leading to discontinuation of the drugs or placebo, 2.1% vs. 4.2%).Dysgeusia (5.6% vs. 0.3%) and diarrhea (3.1% vs. 1.6%) occurred more frequently with nirmatrelvir plus ritonavir than with placebo. CONCLUSIONSTreatment of symptomatic Covid-19 with nirmatrelvir plus ritonavir resulted in a risk of progression to severe Covid-19 that was 89% lower than the risk with placebo, without evident safety concerns.(Supported by Pfizer; ClinicalTrials.govnumber, NCT04960202.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa2118542

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention
Wu, Z., & McGoogan, J. M. (2020) · JAMA · doi:10.1001/jama.2020.2648 · Cited by 17,016
Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019
Roth, G. A., Mensah, G. A., Johnson, C. O., Addolorato, G., Ammirati, E., Baddour, L. M., Barengo, N. C., Beaton, A. Z., Benjamin, E. J., Benziger, C. P., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.11.010 · Cited by 11,449
Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19·2 million participants.
(2016) · The Lancet · doi:10.1016/s0140-6736(16)30054-x · Cited by 5,212
SARS-CoV-2 variants, spike mutations and immune escape
Harvey, W. T., Carabelli, A. M., Jackson, B., Gupta, R. K., Thomson, E. C., Harrison, E. M., Ludden, C., Reeve, R., Rambaut, A., COVID-19 Genomics UK (COG-UK) Consortium, et al. (2021) · Nature Reviews Microbiology · doi:10.1038/s41579-021-00573-0 · Cited by 3,528
Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study
Docherty, A. B., Harrison, E. M., Green, C. A., Hardwick, H. E., Pius, R., Norman, L., Holden, K. A., Read, J. M., Dondelinger, F., Carson, G., et al. (2020) · BMJ · doi:10.1136/bmj.m1985 · Cited by 3,481
A Multiple Testing Procedure for Clinical Trials
O'Brien, P. C., & Fleming, T. R. (1979) · Biometrics · doi:10.2307/2530245 · Cited by 3,311
Discrete Sequential Boundaries for Clinical Trials
Lan, K. K. G., & DeMets, D. L. (1983) · Biometrika · doi:10.2307/2336502 · Cited by 2,310
Discrete sequential boundaries for clinical trials
GORDON LAN, K. K., & DEMETS, D. L. (1983) · Biometrika · doi:10.1093/biomet/70.3.659 · Cited by 2,310
Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis
Zheng, Z., Peng, F., Xu, B., Zhao, J., Liu, H., Peng, J., Li, Q., Jiang, C., Zhou, Y., Liu, S., et al. (2020) · Journal of Infection · doi:10.1016/j.jinf.2020.04.021 · Cited by 2,074
An oral SARS-CoV-2 M pro inhibitor clinical candidate for the treatment of COVID-19
Owen, D. R., Allerton, C. M. N., Anderson, A. S., Aschenbrenner, L., Avery, M., Berritt, S., Boras, B., Cardin, R. D., Carlo, A., Coffman, K. J., et al. (2021) · Science · doi:10.1126/science.abl4784 · Cited by 2,033

Flagged first, then by citations

Show all 21 references

Sorted by citations

Items 601–700 of 1,002

Heparin Inhibits SARS-CoV-2 Replication in Human Nasal Epithelial Cells
Lee, L., Suryadinata, R., McCafferty, C., Ignjatović, V., Purcell, D. F. J., Robinson, P. J., Morton, C. J., Parker, M. W., Anderson, G. P., Monagle, P., et al. (2022) · Viruses · doi:10.3390/v14122620 · Cited by 13
Paxlovid-Induced Symptomatic Bradycardia and Syncope
Ganipisetti, V. M., Bollimunta, P., & Maringanti, B. S. (2023) · Cureus · doi:10.7759/cureus.33831 · Cited by 13
Dry powder formulation of azithromycin for COVID-19 therapeutics
Chan, S. H. Y., Sheikh, K., Zariwala, M. G., & Somavarapu, S. (2023) · Journal of Microencapsulation · doi:10.1080/02652048.2023.2175924 · Cited by 13
Clinical effectiveness of nirmatrelvir plus ritonavir in patients with COVID‐19 and substance use disorders based on real‐world data
Liu, T., Huang, P., Wu, J., Chuang, M., Hsu, W., Tsai, Y., Chang, C., & Lai, C. (2023) · Journal of Medical Virology · doi:10.1002/jmv.28801 · Cited by 13
2023 Chinese expert consensus on the impact of COVID-19 on the management of cardiovascular diseases
Branch of Cardiovascular Physicians of Chinese Medical Doctor Association (2023) · Cardiology Plus · doi:10.1097/cp9.0000000000000043 · Cited by 13
Expert Consensus: Main Risk Factors for Poor Prognosis in COVID-19 and the Implications for Targeted Measures against SARS-CoV-2
Candel, F. J., Barreiro, P., Salavert, M., Cabello, A., Fernández‐Ruiz, M., Pérez‐Segura, P., Román, J. S., Berenguer, J., Córdoba, R., Delgado, R. B., et al. (2023) · Viruses · doi:10.3390/v15071449 · Cited by 14
Aprotinin—Drug against Respiratory Diseases
Ivachtchenko, A. V., Ivashchenko, A. A., Shkil, D. O., & Ivashchenko, I. A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241311173 · Cited by 13
Efficacy and safety of Huashi Baidu granule plus Nirmatrelvir-Ritonavir combination therapy in patients with high-risk factors infected with Omicron (B.1.1.529): A multi-arm single-center, open-label, randomized controlled trial
Yu, Z., Zheng, Y., Chen, B., Lv, J., Zhu, X., Shang, B., Xv, Y., Ru, T., Yang, Y., Cong, J., et al. (2023) · Phytomedicine · doi:10.1016/j.phymed.2023.155025 · Cited by 13
COVID‐19 after hematopoietic cell transplantation and chimeric antigen receptor (CAR)‐T‐cell therapy
Kampouri, E., Hill, J. A., & Dioverti, M. V. (2023) · Transplant Infectious Disease · doi:10.1111/tid.14144 · Cited by 13
Using alternative SMILES representations to identify novel functional analogues in chemical similarity vector searches
Kosonocky, C. W., Feller, A. L., Wilke, C. O., & Ellington, A. D. (2023) · Patterns · doi:10.1016/j.patter.2023.100865 · Cited by 16
Effectiveness of nirmatrelvir‐ritonavir on severe outcomes of COVID‐19 in the era of vaccination and Omicron: An updated meta‐analysis
Ombelet, S., Castanares‐Zapatero, D., Desimpel, F., Hulstaert, F., Stordeur, S., & Roberfroid, D. (2024) · Journal of Medical Virology · doi:10.1002/jmv.29434 · Cited by 13
Effectiveness and safety of Sanhan Huashi granules versus nirmatrelvir–ritonavir in adult patients with COVID-19: A randomized, open-label, multicenter trial
Zou, X., Chang, K., Fan, G., Zheng, H., Shen, H., Tang, L., Yang, Y., Wang, Y., Zhao, L., Lv, H., et al. (2024) · 中国科学通报：英文版 · doi:10.1016/j.scib.2024.04.040 · Cited by 13
Nirmatrelvir Resistance in an Immunocompromised Patient with Persistent Coronavirus Disease 2019
Yamamoto, C., Taniguchi, M., Furukawa, K., Inaba, T., Niiyama, Y., Ide, D., Mizutani, S., Kuroda, J., Tanino, Y., Nishioka, K., et al. (2024) · Viruses · doi:10.3390/v16050718 · Cited by 13
Efficacy of late-onset antiviral treatment in immunocompromised hosts with persistent SARS-CoV-2 infection
Lieber, C. M., Kang, H., Sobolik, E. B., Sticher, Z. M., Ngo, V. L., Gewirtz, A. T., Kolykhalov, A. A., Natchus, M. G., Greninger, A. L., Suthar, M. S., et al. (2024) · Journal of Virology · doi:10.1128/jvi.00905-24 · Cited by 13
An oral non-covalent non-peptidic inhibitor of SARS-CoV-2 Mpro ameliorates viral replication and pathogenesis in vivo
Zhou, N., Tang, S., Bian, X., Parai, M. K., Krieger, I. V., Flores, A., Jaiswal, P. K., Bam, R., Wood, J. L., Shi, Z., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114929 · Cited by 13
Harnessing antiviral RNAi therapeutics for pandemic viruses: SARS-CoV-2 and HIV
Bowden-Reid, E., Moles, E., Kelleher, A. D., & Ahlenstiel, C. (2025) · Drug Delivery and Translational Research · doi:10.1007/s13346-025-01788-x · Cited by 15
Interplay between respiratory viruses and cilia in the airways
Horton, K. L., Wing, P. A. C., Jackson, C. L., McCormick, C. J., Carroll, M. P., & Lucas, J. S. (2025) · European Respiratory Review · doi:10.1183/16000617.0224-2024 · Cited by 15
Efficacy and safety of obeldesivir in low-risk, non-hospitalised patients with COVID-19 (OAKTREE): a phase 3, randomised, double-blind, placebo-controlled study
Ogbuagu, O. E., Goldman, J. D., Gottlieb, R., Singh, U., Shinkai, M., Acloque, G., Fusco, D. N., Gonzalez, E., Kumar, P. N., Luetkemeyer, A. F., et al. (2025) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(25)00238-5 · Cited by 13
Oral drugs against COVID-19
Mikus, G., Foerster, K. I., Terstegen, T., Vogt, C. J., Said, A., Schulz, M., & Haefeli, W. E. (2022) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.m2022.0152 · Cited by 13
Advances in the epidemiology, clinical features, diagnosis, clinical management and prevention of coronavirus disease 2019
Hui, D. S. C., & Zumla, A. I. (2022) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000875 · Cited by 13
Homo-harringtonine, highly effective against coronaviruses, is safe in treating COVID-19 by nebulization
Ma, H., Wen, H., Qin, Y., Wu, S., Zhang, G., Wu, C., & Cai, Q. (2022) · Science China Life Sciences · doi:10.1007/s11427-021-2093-2 · Cited by 13
PF ‐07321332 (Nirmatrelvir) does not interact with human ENT1 or ENT2 : Implications for COVID ‐19 patients
Hau, R. K., Wright, S. H., & Cherrington, N. J. (2022) · Clinical and Translational Science · doi:10.1111/cts.13292 · Cited by 13
Nonproductive exposure of PBMCs to SARS‐CoV‐2 induces cell‐intrinsic innate immune responses
Kazmierski, J., Friedmann, K., Postmus, D., Emanuel, J., Fischer, C., Jansen, J., Richter, A. M., de Jarcy, L. B., Schüler, C., Sohn, M., et al. (2022) · Molecular Systems Biology · doi:10.15252/msb.202210961 · Cited by 15
A Pilot Trial of Thymalfasin (Thymosin-α-1) to Treat Hospitalized Patients With Hypoxemia and Lymphocytopenia Due to Coronavirus Disease 2019 Infection
Shehadeh, F., Benitez, G., Mylona, E. K., Tran, Q., Tsikala-Vafea, M., Atalla, E., Kaczynski, M., & Mylonakis, E. E. (2022) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiac362 · Cited by 13
Drugs for the prevention and treatment of COVID-19 and its complications: An update on what we learned in the past 2 years
Remuzzi, G., Schiaffino, S., Santoro, M. G., FitzGerald, G. A., Melino, G., & Patrono, C. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.987816 · Cited by 16
Optimizing variant-specific therapeutic SARS-CoV-2 decoys using deep-learning-guided molecular dynamics simulations
Köchl, K., Schopper, T., Durmaz, V., Parigger, L., Singh, A., Krassnigg, A., Cespugli, M., Wu, W. T., Yang, X., Zhang, Y., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-27636-x · Cited by 13
Pharmacological Activities of Fingerroot Extract and Its Phytoconstituents Against SARS-CoV-2 Infection in Golden Syrian Hamsters
Kongratanapasert, T., Kongsomros, S., Arya, N., Sutummaporn, K., Wiriyarat, W., Akkhawattanangkul, Y., Boonyarattanasoonthorn, T., Asavapanumas, N., Kanjanasirirat, P., Suksatu, A., et al. (2023) · Journal of Experimental Pharmacology · doi:10.2147/jep.s382895 · Cited by 13
Use and effectiveness of remdesivir for the treatment of patients with covid-19 using data from the Lean European Open Survey on SARS-CoV-2 infected patients (LEOSS): a multicentre cohort study
Pilgram, L., Appel, K. S., Ruethrich, M. M., Koll, C. E. M., Vehreschild, M. J. G. T., de Miranda, S. M. N., Hower, M., Hellwig, K., Hanses, F., Wille, K., et al. (2023) · Infection · doi:10.1007/s15010-023-01994-0 · Cited by 13
Safely Prescribing Nirmatrelvir and Ritonavir—Avoiding Drug-Drug Interactions
Culas, R., Nath, S., & Nath, S. (2023) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2022.6834 · Cited by 13
Chronic critical illness in critically ill COVID-19 patients
Halaçlı, B., Yıldırım, M. S., Kaya, E. K., Ulusoydan, E., Ersoy, E. O., & Topeli̇, A. (2023) · Chronic Illness · doi:10.1177/17423953231161333 · Cited by 13
Modulation of in Vitro SARS-CoV-2 Infection by Stephania tetrandra and Its Alkaloid Constituents
Khadilkar, A., Bunch, Z. L., Wagoner, J., Ravindran, V., Oda, J. M., Vidar, W. S., Clark, T. N., Manwill, P. K., Todd, D. A., Barr, S. A., et al. (2023) · Journal of Natural Products · doi:10.1021/acs.jnatprod.3c00159 · Cited by 13
A Phase 2 Randomized Trial Evaluating the Antiviral Activity and Safety of the Direct-Acting Antiviral Bemnifosbuvir in Ambulatory Patients with Mild or Moderate COVID-19 (MOONSONG Study)
Boffito, M., Dolan, E., Singh, K., Holmes, W. C., Wildum, S., Horga, A., Pietropaolo, K., Zhou, X., Clinch, B., Collinson, N., et al. (2023) · Microbiology Spectrum · doi:10.1128/spectrum.00077-23 · Cited by 13
Effectiveness of molnupiravir vs nirmatrelvir-ritonavir in non-hospitalised and hospitalised patients with COVID-19: a target trial emulation study
Wan, E. Y. F., Yan, V. K. C., Wong, Z. C. T., Chui, C. S. L., Lai, F. T. T., Li, X., Wong, C. K. H., Hung, I. F., Lau, C. S., Wong, I. C. K., et al. (2023) · EClinicalMedicine · doi:10.1016/j.eclinm.2023.102225 · Cited by 13
Azvudine and nirmatrelvir–ritonavir in hospitalized patients with moderate‐to‐severe COVID‐19: Emulation of a randomized target trial
Zhou, Y., Liu, Y., Jiang, L., Zhang, R., Zhang, H., Shi, Q., Yang, Z., Mao, Y., Liu, S., Yang, Z., et al. (2023) · Journal of Medical Virology · doi:10.1002/jmv.29318 · Cited by 13
Interaction and antiviral treatment of coinfection between SARS-CoV-2 and influenza in vitro
Liu, D., Leung, K., Lam, H., Zhang, R., Fan, Y., Xie, X., Chan, K., & Hung, I. F. (2024) · Virus Research · doi:10.1016/j.virusres.2024.199371 · Cited by 13
Drug repurposing based on a quantum-inspired method versus classical fingerprinting uncovers potential antivirals against SARS-CoV-2
Jiménez-Guardeño, J. M., Ortega‐Prieto, A. M., Moreno, B. M., Maguire, T. J. A., Richardson, A., Díaz‐Hernandéz, J. I., Pérez, J. D., Zuckerman, M. A., Playa, A. M., Deline, C. C., et al. (2022) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1010330 · Cited by 13
Risk/Benefit Profiles of Currently Approved Oral Antivirals for Treatment of COVID-19: Similarities and Differences
Corritori, S., Savchuk, N., & Pauza, C. D. (2022) · COVID · doi:10.3390/covid2080078 · Cited by 13
Paxlovid (nirmatrelvir/ritonavir) effectiveness against hospitalization and death in N3C: A target trial emulation studyPreprint
Hansen, K., Makkar, S. R., Sahner, D., Fessel, J. P., Hotaling, N. A., & Sidky, H. (2023) · medRxiv · doi:10.1101/2023.05.26.23290602 · Cited by 13
SARS-CoV-2 Pneumonia: Advances in Diagnosis and Treatment
Căliman-Sturdza, O. A., Șoldănescu, I., & Gheorghita, R. E. (2025) · Microorganisms · doi:10.3390/microorganisms13081791 · Cited by 12
Oral Nirmatrelvir–Ritonavir for Covid-19 in Higher-Risk Outpatients
Butler, C. C., Pinto, A., Harris, V., Holmes, J., Rahman, N. M., Cureton, L., Hayward, G., Richards, D. B., Lowe, D. M., Standing, J. F., et al. (2026) · New England Journal of Medicine · doi:10.1056/nejmoa2502457 · Cited by 12
The Performance of Lateral Flow Tests in the Age of the Omicron: A Rapid Systematic Review
Ng, Q. X., Lim, Y. L., Han, M. X., Teoh, S. E., Thumboo, J., & Tan, B. H. (2022) · Life · doi:10.3390/life12111941 · Cited by 12
Allogeneic hematopoietic stem cell transplantation in the COVID-19 era
Bordat, J., Maury, S., & Leclerc, M. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1100468 · Cited by 13
Azvudine and mortality in patients with coronavirus disease 2019: A retrospective cohort study
Liu, B., Yang, M., Xu, L., Li, Y., Cai, J., Xie, B., Zong, K., & Guo, S. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110824 · Cited by 12
Lichen or Associated Micro-Organism Compounds Are Active against Human Coronaviruses
Desmarets, L. M. B., Millot, M., Chollet‐Krugler, M., Boustié, J., Camuzet, C., François, N., Rouillé, Y., Belouzard, S., Tomasi, S., Mambu, L., et al. (2023) · Viruses · doi:10.3390/v15091859 · Cited by 12
Outcomes of targeted treatment in immunocompromised patients with asymptomatic or mild COVID-19: a retrospective study
Lahouati, M., Cazanave, C., Labadie, A. L., Gohier, P., Guirle, L., Desclaux, A., Gigan, M., Malvy, D. J.-M., Pedeboscq, S., Xuereb, F., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-42727-5 · Cited by 12
Paxlovid mouth likely is mediated by activation of the TAS2R1 bitter receptor by nirmatrelvir
Caronia, L., Xi, R., Margolskee, R. F., & Jiang, P. (2023) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2023.10.001 · Cited by 12
Drug repurposing for the treatment of COVID-19: Targeting nafamostat to the lungs by a liposomal delivery system
Reus, P., Guthmann, H., Uhlig, N., Agbaria, M., Issmail, L., Eberlein, V., Nordling‐David, M. M., Jbara-Agbaria, D., Ciesek, S., Bojková, D., et al. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.10.050 · Cited by 12
The interplay of drug therapeutics and immune responses to SARS-CoV-2
Fumagalli, V., & Iannacone, M. (2023) · Cellular and Molecular Immunology · doi:10.1038/s41423-023-01098-7 · Cited by 12
Novel polymer-based hydrogels of recent research in drug delivery for disease treatment related to SARS-CoV-2 virus
Thang, N. H., Phuc, N. V., Nhi, T. T. T., Cường, Đ. X., & Minh, D. Q. (2023) · eXPRESS Polymer Letters · doi:10.3144/expresspolymlett.2024.13 · Cited by 12
Cost-effectiveness of nirmatrelvir/ritonavir for high-risk adult outpatients with COVID-19 in Japan
Mizuno, T., Kondo, Y., Sakai, M., Saneyasu, K., Kojima, R., & Miyake, Y. (2024) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2024.02.001 · Cited by 12
Catalytic Asymmetric Synthesis of Chiral α,α-Dialkyl Aminonitriles via Reaction of Cyanoketimines
Gao, Y., Zeng, Y., Deng, T., Deng, Y., Cheng, C., Luo, J., & Deng, L. (2024) · Journal of the American Chemical Society · doi:10.1021/jacs.4c03333 · Cited by 12
Comparison of safety and efficacy between Nirmatrelvir-ritonavir and molnupiravir in the treatment of COVID-19 infection in patients with advanced kidney disease: a retrospective observational study
Chu, W. M., Wan, E. Y. F., Wong, Z. C. T., Tam, A. R., Wong, I. C. K., Chan, E. W., & Hung, I. F. (2024) · EClinicalMedicine · doi:10.1016/j.eclinm.2024.102620 · Cited by 12
Omicron SARS-CoV-2 infection management and outcomes in patients with hematologic disease and recipients of cell therapy
Piñana, J. L., Vázquez, L., Heras, I. D. L., Aiello, T. F., López‐Corral, L., Arroyo, I., Soler‐Espejo, E., García‐Cadenas, I., García‐Gutiérrez, V., Aroca, C., et al. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1389345 · Cited by 12
Real-world effectiveness of Paxlovid in protecting Long COVID for outpatient adult patients: A target trial emulation study from the RECOVER Initiative
Wang, F., Li, H., Khullar, D., Zhang, Y., Strobel, S., Chen, Y., Sala, M. A., Patel, P. B., Comellas, A. P., Wylam, A., et al. (2026) · PLOS Global Public Health · doi:10.1371/journal.pgph.0005771 · Cited by 12
Preclinical and Clinical Investigations of Potential Drugs and Vaccines for COVID-19 Therapy: A Comprehensive Review With Recent Update
Mia, M. E., Howlader, M., Akter, F., & Hossain, M. M. (2024) · Clinical Pathology · doi:10.1177/2632010x241263054 · Cited by 12
Discovery of Novel Nonpeptidic and Noncovalent Small Molecule 3CL pro Inhibitors as anti-SARS-CoV-2 Drug Candidate
Jiang, Z., Feng, B., Chen, L., Nie, T., Chen, S., Li, W., Liu, H., Yu, T., Zhang, Y., Zheng, M., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c00739 · Cited by 12
Antiviral efficacy of fluoxetine in early symptomatic COVID-19: an open-label, randomised, controlled, adaptive platform trial (PLATCOV)
Jittamala, P., Boyd, S., Schilling, W. H., Watson, J. A., Ngamprasertchai, T., Siripoon, T., Luvira, V., Batty, E. M., Wongnak, P., Esper, L., et al. (2025) · EClinicalMedicine · doi:10.1016/j.eclinm.2024.103036 · Cited by 12
Management of SARS-CoV-2 Infection-Clinical Practice Guidelines of the Polish Association of Epidemiologists and Infectiologists, for 2025
Flisiak, R., Jaroszewicz, J., Kozielewicz, D., Kuchar, E. P., Parczewski, M., Pawłowska, M., Piekarska, A., Rzymski, P., Simon, K. A., Tomasiewicz, K., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14072305 · Cited by 13
The immunopathogenesis of SARS-CoV-2 infection: Overview of lessons learned in the first 5 years
Yang, O. O. (2025) · The Journal of Immunology · doi:10.1093/jimmun/vkaf033 · Cited by 14
Molnupiravir or nirmatrelvir–ritonavir plus usual care versus usual care alone in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Abani, O., Abbas, A., Abbas, F., Abbas, J., Abbas, K., Abbas, M. A., Abbasi, S., Abbass, H., Abbott, A., Abdallah, N., et al. (2025) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(25)00093-3 · Cited by 12
Unfolding photo-degradation/reduction activity of heterojunction-derived g-C3N4/Sm2O3 for sustainable remediation of antibiotics and organic pollutants
Mishra, P. P., Mohanty, C., Behera, A. K., Das, R., & Das, N. (2025) · Journal of Rare Earths · doi:10.1016/j.jre.2025.06.020 · Cited by 12
Effects of Baloxavir Marboxil Plus Neuraminidase Inhibitor vs Neuraminidase Inhibitor in High-risk Patients Hospitalized With Severe Influenza: A Post Hoc Analysis of the Flagstone Trial
Yan, M., Gu, X., Wang, Y., & Cao, B. (2025) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofaf439 · Cited by 12
A randomized, double-blind, placebo-controlled trial of niclosamide nanohybrid for the treatment of patients with mild to moderate COVID-19
Kim, J. H., Kym, S., Kim, S., Park, D. W., Kwon, K. T., Seo, J.-W., Yu, S., Choi, G., Rejinold, N. S., Choy, J., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-62423-4 · Cited by 12
COVID-19 and Cancer: Special Considerations for Patients Receiving Immunotherapy and Immunosuppressive Cancer Therapies
Goldman, J. D., Gonzalez, M. A., Rüthrich, M. M., Sharon, E., & von Lilienfeld‐Toal, M. (2022) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_359656 · Cited by 12
Ensuring Widespread and Equitable Access to Treatments for COVID-19
Vasan, A., Foote, M., & Long, T. G. (2022) · JAMA · doi:10.1001/jama.2022.13554 · Cited by 12
Insights into CD24 and Exosome Physiology and Potential Role in View of Recent Advances in COVID-19 Therapeutics: A Narrative Review
Tsioulos, G., Grigoropoulos, I., Moschopoulos, C. D., Shapira, S., Poulakou, G., Antoniadou, A., Boumpas, D. T., Arber, N., & Tsiodras, S. (2022) · Life · doi:10.3390/life12101472 · Cited by 12
Sensitivity and Diagnostic Yield of the First SARS-CoV-2 Nucleic Acid Amplification Test Performed for Patients Presenting to the Hospital
Hohl, C. M., Hau, J. P., Vaillancourt, S., Grant, J. L., Brooks, S. C., Morrison, L. J., Perry, J. J., Rosychuk, R. J., CCEDRRN investigators for the Network of Canadian Emergency Researchers and the Canadian Critical Care Trials Group, Martin, I. B. K., et al. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.36288 · Cited by 12
Clinical conundrums involving statin drug-drug interactions
Lamprecht, D. G., Saseen, J. J., & Shaw, P. B. (2022) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2022.11.002 · Cited by 12
Recent changes in the mutational dynamics of the SARS-CoV-2 main protease substantiate the danger of emerging resistance to antiviral drugs
Parigger, L., Krassnigg, A., Schopper, T., Singh, A., Tappler, K., Köchl, K., Hetmann, M., Gruber, K. F., Steinkellner, G., & Gruber, C. C. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.1061142 · Cited by 12
Update on COVID-19 Therapy in Pediatric Age
Esposito, S., Autore, G., Argentiero, A., Ramundo, G., Perrone, S., & Principi, N. (2022) · Pharmaceuticals · doi:10.3390/ph15121512 · Cited by 12
Is the 4C Score Still a Valid Item to Predict In-Hospital Mortality in People with SARS-CoV-2 Infections in the Omicron Variant Era?
VITO, A. D., Colpani, A., Saderi, L., Puci, M. V., Zauli, B., Meloni, M. C., Fois, M., Bitti, A., Castri, C. D., Fiore, V., et al. (2023) · Life · doi:10.3390/life13010183 · Cited by 12
Outcomes of breakthrough COVID-19 infections in patients with hematologic malignancies
Chien, K. S., Peterson, C. B., Young, E. J., Chihara, D., Manasanch, E. E., Ramdial, J., & Thompson, P. A. (2023) · Blood Advances · doi:10.1182/bloodadvances.2022008827 · Cited by 13
Effect of remdesivir on adverse kidney outcomes in hospitalized patients with COVID-19 and impaired kidney function
Seethapathy, R., Wang, Q., Zhao, S. J., Strohbehn, I. A., Long, J. D., Dinulos, J. E., Harden, D., Kadiyala, V. B., Moreno, D., & Sise, M. E. (2023) · PLoS ONE · doi:10.1371/journal.pone.0279765 · Cited by 12
1-O-Octadecyl-2-O-benzyl-sn-glyceryl-3-phospho-GS-441524 (V2043). Evaluation of Oral V2043 in a Mouse Model of SARS-CoV-2 Infection and Synthesis and Antiviral Evaluation of Additional Phospholipid Esters with Enhanced Anti-SARS-CoV-2 Activity
Carlin, A. F., Beadle, J. R., Clark, A. E., Gully, K. L., Moreira, F. R., Baric, R. S., Graham, R. L., Valiaeva, N., Leibel, S. L., Bray, W. A., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00046 · Cited by 12
Oral anti‐viral therapy for early COVID ‐19 infection in patients with haematological malignancies: A multicentre prospective cohort
Minoia, C., Diella, L., Perrone, T., Loseto, G., Pelligrino, C., Attolico, I., Pasciolla, C., Totaro, V., Candia, M. S. D., Spada, V., et al. (2023) · British Journal of Haematology · doi:10.1111/bjh.18895 · Cited by 12
Pan-American Guidelines for the treatment of SARS-CoV-2/COVID-19: a joint evidence-based guideline of the Brazilian Society of Infectious Diseases (SBI) and the Pan-American Association of Infectious Diseases (API)
Barbosa, A. N., Chebabo, A., Starling, C. E. F., Pérez, C., da Cunha, C. A., de Luna, D., Nunes, E. P., Zambrano, G., Ferreira, J. C., Croda, J., et al. (2023) · Annals of Clinical Microbiology and Antimicrobials · doi:10.1186/s12941-023-00623-w · Cited by 14
A model-based pharmacokinetic assessment of drug–drug interaction between tacrolimus and nirmatrelvir/ritonavir in a kidney transplant patient with COVID-19
Tomida, T., Itohara, K., Yamamoto, K., Kimura, T., Fujita, K., Uda, A., Kitahiro, Y., Yokoyama, N., Hyodo, Y., Omura, T., et al. (2023) · Drug Metabolism and Pharmacokinetics · doi:10.1016/j.dmpk.2023.100529 · Cited by 12
A Review of Hematological Complications and Treatment in COVID-19
Yazdani, A. N., Abdi, A., Velpuri, P., Patel, P. R., DeMarco, N., Agrawal, D. K., & Rai, V. (2023) · Hematology Reports · doi:10.3390/hematolrep15040059 · Cited by 12
E3 ubiquitin ligase ZBTB25 suppresses beta coronavirus infection through ubiquitination of the main viral protease MPro
Lear, T., Boudreau, Á. N., Lockwood, K. C., Chu, E., Camarco, D. P., Cao, Q., Nguyen, M. K., Evankovich, J. W., Finkel, T., Liu, Y., et al. (2023) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2023.105388 · Cited by 12
Bioluminescence imaging reveals enhanced SARS-CoV-2 clearance in mice with combinatorial regimens
Ullah, I., Escudié, F., Scandale, I., Gilani, Z., Gendron‐Lepage, G., Gaudette, F., Mowbray, C. E., Fraisse, L., Bazin, R., Finzi, A., et al. (2024) · iScience · doi:10.1016/j.isci.2024.109049 · Cited by 12
CCR5/CXCR3 antagonist TAK-779 prevents diffuse alveolar damage of the lung in the murine model of the acute respiratory distress syndrome
Чернов, А. С., Rodionov, M. V., Kazakov, V. A., Ivanova, K. A., Meshcheryakov, F. A., Kudriaeva, A. A., Gabibov, A. G., Telegin, G. B., & Belogurov, A. A. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1351655 · Cited by 13
A retrospective cohort study of Paxlovid efficacy depending on treatment time in hospitalized COVID-19 patients
Du, Z., Wang, L., Bai, Y., Liu, Y., Lau, E. H. Y., Galvani, A. P., Krug, R. M., Cowling, B. J., & Meyers, L. A. (2024) · eLife · doi:10.7554/elife.89801 · Cited by 12
Post-COVID Interstitial Lung Disease—The Tip of the Iceberg
Kewalramani, N., Heenan, K.-M., McKeegan, D., & Chaudhuri, N. (2023) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2023.01.004 · Cited by 12
Viral Load Rebound in Placebo and Nirmatrelvir-Ritonavir Treated COVID-19 Patients is not Associated with Recurrence of Severe Disease or MutationsPreprint
Soares, H. D., Baniecki, M. L., Cardin, R. D., Leister-Tebbe, H. K., Zhu, Y., Guan, S., Hyde, C. L., He, W., Wang, Z., Li, H., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1720472/v2 · Cited by 12
Self-citation
Nirmatrelvir for Nonhospitalized Adults with Covid-19
Chen, B. S., Hung, C.-H., & Wei, J. C.-C. (2022) · New England Journal of Medicine · doi:10.1056/nejmc2206277 · Cited by 12
Use of Ritonavir-Boosted Nirmatrelvir in Pregnancy
Siberry, G. K., MOFENSON, L. M., Calmy, A., Reddy, U. M., & Abrams, E. J. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac666 · Cited by 12
Within‐host dynamics of SARS‐CoV‐2 infection: A systematic review and meta‐analysis
Du, Z., Wang, S., Bai, Y., Gao, C., Lau, E. H. Y., & Cowling, B. J. (2022) · Transboundary and Emerging Diseases · doi:10.1111/tbed.14673 · Cited by 11
Early Adoption of Anti–SARS-CoV-2 Pharmacotherapies Among US Veterans With Mild to Moderate COVID-19, January and February 2022
Bajema, K. L., Wang, X. Q., Hynes, D. M., Rowneki, M., Hickok, A. W., Cunningham, F. E., Bohnert, A. S. B., Boyko, E. J., Iwashyna, T. J., Maciejewski, M. L., et al. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.41434 · Cited by 11
Time from symptoms onset to remdesivir is associated with the risk of ICU admission: a multicentric analyses
Alonso-Navarro, R., Ramírez, M., Masiá, M., Paredes, R., Montejano, R., Povar-Echeverría, M., Carratalà, J., Salavert, M., Bernal, E., Dueñas, C., et al. (2023) · BMC Infectious Diseases · doi:10.1186/s12879-023-08222-y · Cited by 11
Prevalence of inappropriate use of nirmatrelvir-ritonavir antiviral therapy in hospitalized patients: A multi-centre retrospective study in China
Shi, C., Qiu, L., Zhuo, J., Fang, Y., Wang, L., Xia, J., Wang, S., Luo, Q., Zhou, K., Li, Y., et al. (2023) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2023.106857 · Cited by 11
Clinical effectiveness of nirmatrelvir plus ritonavir in the treatment of COVID-19 in patients with cirrhosis
Hsu, W., Shiau, B.-W., Liu, T., Wu, J., Tsai, Y., Huang, P., Chuang, M., Lai, C., & Chen, C.-H. (2023) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2023.2267846 · Cited by 11
Vaccination and Antiviral Treatment Reduce the Time to Negative SARS-CoV-2 Swab: A Real-Life Study
VITO, A. D., Moi, G., Saderi, L., Puci, M. V., Colpani, A., Firino, L., Puggioni, A., Uzzau, S., Babudieri, S., Sotgiu, G., et al. (2023) · Viruses · doi:10.3390/v15112180 · Cited by 11
Effectiveness of nirmatrelvir/ritonavir in children and adolescents aged 12–17 years following SARS-CoV-2 Omicron infection: A target trial emulation
Wong, C. K. H., Lau, K. T. K., Au, I. C. H., Chan, H. S., Lau, E. H. Y., Cowling, B. J., & Leung, G. M. (2024) · Nature Communications · doi:10.1038/s41467-024-49235-8 · Cited by 11
Automated self-optimization of continuous crystallization of nirmatrelvir API
Nandiwale, K. Y., Pritchard, R. P., Armstrong, C. T., Guinness, S. M., & Girard, K. P. (2024) · Reaction Chemistry & Engineering · doi:10.1039/d4re00272e · Cited by 11
Molecular Mechanism-Driven Discovery of Novel Small Molecule Inhibitors against Drug-Resistant SARS-CoV-2 Mpro Variants
Yang, J., Fu, B., Gou, R., Lin, X., Wu, H., & Xue, W. (2024) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.4c01206 · Cited by 11
Real-world analysis of safety, tolerability, and adherence to nirmatrelvir-ritonavir (paxlovid) in primary care COVID-19 outpatients
Zaharuddin, Z., Hussin, N. S. M., & Karuppannan, M. (2024) · Scientific Reports · doi:10.1038/s41598-024-75192-9 · Cited by 11
An orally available P1′-5-fluorinated Mpro inhibitor blocks SARS-CoV-2 replication without booster and exhibits high genetic barrier
Higashi‐Kuwata, N., Bulut, H., Hayashi, H., Tsuji, K., Ogata-Aoki, H., Kiso, M., Takamune, N., Kishimoto, N., Hattori, S.-I., Ishii, T. M., et al. (2024) · PNAS Nexus · doi:10.1093/pnasnexus/pgae578 · Cited by 12
Measures to Prevent and Control COVID-19 in Skilled Nursing Facilities
Canter, B. E., Ulytė, A., McGarry, B. E., & Barnett, M. L. (2025) · JAMA Health Forum · doi:10.1001/jamahealthforum.2024.5175 · Cited by 11
Serum Spike Protein Persistence Post COVID Is Not Associated with ME/CFS
Fehrer, A., Sotzny, F., Hoheisel, F., Stein, E., Kim, L., Kedor, C., Freitag, H., Heindrich, C., Bauer, S., Rust, R., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14041086 · Cited by 11
Clinical and molecular landscape of prolonged SARS-CoV-2 infection with resistance to remdesivir in immunocompromised patients
Iriyama, C., Ichikawa, T., Tamura, T., Takahata, M., Ishio, T., Ibata, M., Kawai, R., Iwata, M., Suzuki, M., Adachi, H., et al. (2025) · PNAS Nexus · doi:10.1093/pnasnexus/pgaf085 · Cited by 11

Authors: Hammond, J., Leister-Tebbe, H., Gardner, A., Abreu, P., Bao, W., Wisemandle, W., Baniecki, M., Hendrick, V. M., Damle, B., Simón-Campos, A., Pypstra, R., & Rusnak, J. M.
Affiliations: Pfizer (United States) (US)
From Global Product Development, Pfizer, Collegeville, PA (J.H., H.L.-T.); Global Product Development (A.G.) and Early Clinical Development (M.L.B.), Pfizer, Cambridge, MA; Global Product Development, Pfizer, New York (P.A., W.B., B.D., R.P.); Global Product Development, Pfizer, Lake Forest, IL (W.W.); Medical and Safety, Pfizer, Sandwich, United Kingdom (V.M.H.); Köhler and Milstein Research, Mérida, Yucatan, Mexico (A.S.-C.); and Global Product Development, Pfizer, Tampa, FL (J.M.R.).
Corresponding author: Hammond, Jennifer
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2022-04-14
Volume: 386
Issue: 15
Pages: 1397-1408
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa2118542
PMC: PMC8908851
OpenAlex: W4212904481
Cited by: 2,323
References: 21
Citations by year: 2026: 186 · 2025: 319 · 2024: 517 · 2023: 769 · 2022: 525
FWCI: 261.43
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.nejmgroup.org/legal/terms-of-use.htm (vor)
Locations: New England Journal of Medicine (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Funders: Pfizer
Topics: Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
Health Sciences › Medicine › Epidemiology › Respiratory viral infections research
Keywords: nirmatrelvir, COVID-19 pandemic, SARS-CoV-2, Mpro inhibitors, ritonavir, oral antiviral therapy, high-risk adults, non-hospitalized patients, viral load, unvaccinated patients, early treatment, SARS-CoV-2 variants, Omicron variant
MeSH terms: Viral Protease Inhibitors, COVID-19, SARS-CoV-2, COVID-19 Drug Treatment, Administration, Oral, Adult, Antiviral Agents, Double-Blind Method, Drug Combinations, Hospitalization, Humans, Lactams, Leucine, Nitriles, Proline, Vaccination, Treatment Outcome, Disease Progression, Ritonavir, Viral Load

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks